Akoya Biosciences Inc (AKYA)

$3.995

-0.13

(-3.27%)

Live

Insights on Akoya Biosciences Inc

  • Increasing Revenue

    Revenue is up for the last 12 quarters, 12.21M → 26.48M (in $), with an average increase of 6.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -20.80M → -10.80M (in $), with an average increase of 40.3% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 44.1% return, outperforming this stock by 85.4%

Performance

  • $3.96
    $4.15
    $4.00
    downward going graph

    1.0%

    Downside

    Day's Volatility :4.58%

    Upside

    3.61%

    downward going graph
  • $3.04
    $8.80
    $4.00
    downward going graph

    24.0%

    Downside

    52 Weeks Volatility :65.45%

    Upside

    54.55%

    downward going graph

Returns

PeriodAkoya Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-6.98%
-1.1%
0.0%
6 Months
17.66%
6.7%
0.0%
1 Year
-44.93%
3.2%
-0.7%
3 Years
-84.15%
15.2%
-21.6%

Highlights

Market Capitalization
203.0M
Book Value
$1.1
Earnings Per Share (EPS)
-1.43
Wall Street Target Price
8.83
Profit Margin
-65.53%
Operating Margin TTM
-33.31%
Return On Assets TTM
-19.65%
Return On Equity TTM
-112.72%
Revenue TTM
96.6M
Revenue Per Share TTM
2.17
Quarterly Revenue Growth YOY
24.8%
Gross Profit TTM
43.4M
EBITDA
-47.1M
Diluted Eps TTM
-1.43
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.83
EPS Estimate Next Year
-0.52
EPS Estimate Current Quarter
-0.27
EPS Estimate Next Quarter
-0.24

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Akoya Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 121.03%

Current $4.00
Target $8.83

Company Financials

FY19Y/Y Change
Revenue
42.2M
-
Net Income
-14.8M
-
Net Profit Margin
-34.93%
-
FY20Y/Y Change
Revenue
42.4M
↑ 0.49%
Net Income
-16.7M
↑ 13.25%
Net Profit Margin
-39.36%
↓ 4.43%
FY21Y/Y Change
Revenue
54.9M
↑ 29.39%
Net Income
-42.9M
↑ 157.0%
Net Profit Margin
-78.18%
↓ 38.82%
FY22Y/Y Change
Revenue
74.9M
↑ 36.31%
Net Income
-70.6M
↑ 64.53%
Net Profit Margin
-94.37%
↓ 16.19%
FY23Y/Y Change
Revenue
96.6M
↑ 29.09%
Net Income
-63.3M
↓ 10.36%
Net Profit Margin
-65.53%
↑ 28.84%
Q3 FY22Q/Q Change
Revenue
18.9M
↑ 5.35%
Net Income
-17.9M
↑ 2.15%
Net Profit Margin
-94.8%
↑ 2.97%
Q4 FY22Q/Q Change
Revenue
21.2M
↑ 12.56%
Net Income
-18.9M
↑ 5.61%
Net Profit Margin
-88.95%
↑ 5.85%
Q1 FY23Q/Q Change
Revenue
21.4M
↑ 0.9%
Net Income
-18.8M
↓ 0.39%
Net Profit Margin
-87.82%
↑ 1.13%
Q2 FY23Q/Q Change
Revenue
23.5M
↑ 9.86%
Net Income
-20.8M
↑ 10.64%
Net Profit Margin
-88.44%
↓ 0.62%
Q3 FY23Q/Q Change
Revenue
25.2M
↑ 7.2%
Net Income
-12.9M
↓ 37.91%
Net Profit Margin
-51.22%
↑ 37.22%
Q4 FY23Q/Q Change
Revenue
26.5M
↑ 5.04%
Net Income
-10.8M
↓ 16.37%
Net Profit Margin
-40.78%
↑ 10.44%
FY19Y/Y Change
Total Assets
89.4M
-
Total Liabilities
119.6M
-
FY20Y/Y Change
Total Assets
77.7M
↓ 13.14%
Total Liabilities
59.1M
↓ 50.58%
FY21Y/Y Change
Total Assets
190.9M
↑ 145.82%
Total Liabilities
69.6M
↑ 17.71%
FY22Y/Y Change
Total Assets
176.0M
↓ 7.79%
Total Liabilities
117.5M
↑ 68.86%
FY23Y/Y Change
Total Assets
180.4M
↑ 2.46%
Total Liabilities
126.6M
↑ 7.79%
Q3 FY22Q/Q Change
Total Assets
176.5M
↓ 4.24%
Total Liabilities
101.4M
↑ 8.52%
Q4 FY22Q/Q Change
Total Assets
176.0M
↓ 0.24%
Total Liabilities
117.5M
↑ 15.86%
Q1 FY23Q/Q Change
Total Assets
154.3M
↓ 12.35%
Total Liabilities
112.2M
↓ 4.49%
Q2 FY23Q/Q Change
Total Assets
188.9M
↑ 22.41%
Total Liabilities
117.0M
↑ 4.28%
Q3 FY23Q/Q Change
Total Assets
177.2M
↓ 6.16%
Total Liabilities
115.3M
↓ 1.46%
Q4 FY23Q/Q Change
Total Assets
180.4M
↑ 1.76%
Total Liabilities
126.6M
↑ 9.83%
FY19Y/Y Change
Operating Cash Flow
-13.8M
-
Investing Cash Flow
-12.9M
-
Financing Cash Flow
28.6M
-
FY20Y/Y Change
Operating Cash Flow
-6.8M
↓ 50.33%
Investing Cash Flow
6.7M
↓ 152.19%
Financing Cash Flow
5.5M
↓ 80.79%
FY21Y/Y Change
Operating Cash Flow
-36.1M
↑ 427.08%
Investing Cash Flow
-5.1M
↓ 175.71%
Financing Cash Flow
137.0M
↑ 2397.9%
FY22Y/Y Change
Operating Cash Flow
-53.5M
↑ 48.32%
Investing Cash Flow
-14.1M
↑ 176.38%
Financing Cash Flow
28.7M
↓ 79.04%
Q3 FY22Q/Q Change
Operating Cash Flow
-12.2M
↓ 9.08%
Investing Cash Flow
7.3M
↓ 117.16%
Financing Cash Flow
9.9M
↑ 13.76%
Q4 FY22Q/Q Change
Operating Cash Flow
-10.0M
↓ 17.78%
Investing Cash Flow
22.1M
↑ 204.58%
Financing Cash Flow
10.3M
↑ 4.16%
Q1 FY23Q/Q Change
Operating Cash Flow
-19.8M
↑ 97.44%
Investing Cash Flow
6.2M
↓ 72.0%
Financing Cash Flow
-419.0K
↓ 104.08%
Q2 FY23Q/Q Change
Operating Cash Flow
-11.8M
↓ 40.26%
Investing Cash Flow
-1.4M
↓ 122.97%
Financing Cash Flow
46.3M
↓ 11156.56%

Technicals Summary

Sell

Neutral

Buy

Akoya Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Akoya Biosciences Inc
Akoya Biosciences Inc
-15.89%
17.66%
-44.93%
-84.15%
-84.15%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-2.9%
40.36%
43.11%
43.45%
100.14%
Resmed Inc.
Resmed Inc.
-2.2%
31.59%
-17.56%
-8.98%
80.27%
Becton, Dickinson And Company
Becton, Dickinson And Company
-0.65%
-9.46%
-8.24%
-8.8%
-4.48%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-1.97%
-1.51%
4.84%
22.21%
225.06%
Alcon Ag
Alcon Ag
-4.35%
6.39%
14.92%
9.65%
45.79%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Akoya Biosciences Inc
Akoya Biosciences Inc
NA
NA
NA
-0.83
-1.13
-0.2
NA
1.1
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
76.35
76.35
7.13
6.25
0.15
0.08
NA
37.77
Resmed Inc.
Resmed Inc.
30.77
30.77
1.75
7.41
0.22
0.11
0.01
30.47
Becton, Dickinson And Company
Becton, Dickinson And Company
54.06
54.06
1.34
12.95
0.05
0.03
0.02
87.68
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
49.53
49.53
6.9
7.62
0.21
0.12
0.0
39.2
Alcon Ag
Alcon Ag
41.47
41.47
4.59
3.06
0.05
0.02
0.0
41.81
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Akoya Biosciences Inc
Akoya Biosciences Inc
Buy
$203.0M
-84.15%
NA
-65.53%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$136.4B
100.14%
76.35
25.24%
Resmed Inc.
Resmed Inc.
Buy
$27.3B
80.27%
30.77
19.77%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.9B
-4.48%
54.06
6.44%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$28.5B
225.06%
49.53
20.12%
Alcon Ag
Alcon Ag
Buy
$40.2B
45.79%
41.47
10.3%

Institutional Holdings

  • Blue Water Life Science Advisors, LLC

    9.56%
  • Polar Capital Holdings PLC

    3.21%
  • Vanguard Group Inc

    2.87%
  • BlackRock Inc

    2.79%
  • Parkman Healthcare Partners LLC

    1.37%
  • Uniplan Investment Counsel, Inc.

    1.37%

Corporate Announcements

  • Akoya Biosciences Inc Earnings

    Akoya Biosciences Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

akoya biosciences is developing a novel high-parameter tissue analysis platform, at an order of magnitude beyond what is currently possible. our codex (tm) (co-detection by indexing) system enables deep proteomic profiling.​..all on your existing microscope​. if you are a scientist or software engineer interested in revolutionizing the science of imaging, then akoya is the place for you. contact is at info@akoyabio.com.

Organization
Akoya Biosciences Inc
Employees
330
CEO
Mr. Brian McKelligon
Industry
Healthcare

FAQs